A Forward Look, the Year Ahead - Featured Research on Alnylam Pharmaceuticals, Inc. and ISIS Pharmaceuticals, Inc.
Posted on February 17, 2012 at 09:00 AM EST
HONG KONG -- (Marketwire) -- 02/17/12 -- Today, www.BollingerReport.com introduced featured coverage of Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) and ISIS Pharmaceuticals, Inc. (NASDAQ: ISIS). Full research reports are available to readers at: www.BollingerReport.com/index.php?sm1=ALNY&sm2=ISIS.
Economic fundamentals leading into 2012 have set a generally positive pace with GDP growth likely to pick up through the coming year. However, there are several important caveats to note as the world economy continues to face headwinds and risks weigh to the downside. Positive outlooks are conditional on fiscal policy in payroll taxes and unemployment insurance benefits and upon the easing of the European debt situation. A repeat of volatility experience in 2011 is likely in 2012, as perceptions about the strength of the U.S. economy and the euro zone will vary over time as events unfold.
Despite the current situation, our team continues to identify high momentum situations with growth potential -- there remains strong opportunity within careful discretion.
Bollinger Report screened and selected Alnylam Pharmaceuticals, Inc. for its current position within the healthcare industry. Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company developing therapeutics based on ribonucleic acid interface (RNAi). The RNAi therapeutic program, ALN-RSV01, is in Phase II clinical trials for the treatment of human respiratory syncytial virus (RSV), infection. A copy of this report featuring Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) is available at: www.BollingerReport.com/index.php?sm1=ALNY.
Bollinger Report is featuring ISIS Pharmaceuticals, Inc. for its changing role within the healthcare industry. Isis Pharmaceuticals, Inc. (Isis) is engaged in antisense technology, exploiting a drug discovery platform to create a pipeline of drugs. The Company operates in two business segments: Drug Discovery and Development and Regulus Therapeutics Inc. To download researches and analysis on ISIS Pharmaceuticals, Inc. (NASDAQ: ISIS) we welcome investors to visit: www.BollingerReport.com/index.php?sm2=ISIS.
About Bollinger Report
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Press Release Service provided by PRConnect.
Stock quotes supplied by Telekurs USA
Postage Rates Bots go here